IL229506A0 - Dry powder vancomycin compositions and associated methods - Google Patents
Dry powder vancomycin compositions and associated methodsInfo
- Publication number
- IL229506A0 IL229506A0 IL229506A IL22950613A IL229506A0 IL 229506 A0 IL229506 A0 IL 229506A0 IL 229506 A IL229506 A IL 229506A IL 22950613 A IL22950613 A IL 22950613A IL 229506 A0 IL229506 A0 IL 229506A0
- Authority
- IL
- Israel
- Prior art keywords
- dry powder
- associated methods
- vancomycin compositions
- powder vancomycin
- compositions
- Prior art date
Links
- 108010059993 Vancomycin Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000843 powder Substances 0.000 title 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 title 1
- 229960003165 vancomycin Drugs 0.000 title 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161487971P | 2011-05-19 | 2011-05-19 | |
| PCT/US2012/038775 WO2012159103A1 (en) | 2011-05-19 | 2012-05-21 | Dry powder vancomycin compositions and associated methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL229506A0 true IL229506A0 (en) | 2014-01-30 |
| IL229506B IL229506B (en) | 2019-07-31 |
Family
ID=47177374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL229506A IL229506B (en) | 2011-05-19 | 2013-11-19 | Dry powder vancomycin compositions and associated methods |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2709646A4 (en) |
| JP (1) | JP6012716B2 (en) |
| KR (1) | KR101763195B1 (en) |
| CN (1) | CN103717231B (en) |
| AU (1) | AU2012254999B2 (en) |
| BR (1) | BR112013029803B1 (en) |
| CA (2) | CA2836643C (en) |
| IL (1) | IL229506B (en) |
| MX (1) | MX346244B (en) |
| SG (1) | SG195038A1 (en) |
| WO (1) | WO2012159103A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029994T2 (en) | 2005-12-08 | 2017-04-28 | Insmed Inc | Lipid-based compositions of antiinfectives for treating pulmonary infections |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| BR112015012351A8 (en) * | 2012-11-29 | 2019-10-01 | Insmed Inc | stabilized lipid glycopeptide antibiotic composition and use of a lipid component, a glycopeptide antibiotic component and an amino acid or derivative thereof |
| DK3007689T3 (en) | 2013-01-10 | 2018-06-14 | Pulmokine Inc | NON-SELECTIVE KINASE INHIBITORS |
| CN104043104B (en) * | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | The spray dried powder and its industrialized process for preparing of hydrochloric vancomycin |
| CN111743901B (en) | 2013-10-11 | 2023-09-12 | 普尔莫凯恩股份有限公司 | Spray-dried formulations |
| WO2015128495A1 (en) * | 2014-02-28 | 2015-09-03 | Algipharma As | Use of alginate oligomers in the treatment of cystic fibrosis and other conditions associated with defective cftr ion channel function |
| CN106573037A (en) | 2014-03-14 | 2017-04-19 | 库蒂斯制药公司 | Composition and method for vancomycin oral liquid |
| PL3142643T3 (en) | 2014-05-15 | 2019-12-31 | Insmed Incorporated | Methods for treating pulmonary non-tuberculous mycobacterial infections |
| EA035368B1 (en) * | 2014-11-06 | 2020-06-03 | Кселлия Фармасьютикалз Апс | Glycopeptide compositions |
| AU2016215070B2 (en) * | 2015-02-06 | 2020-09-24 | Latitude Pharmaceuticals, Inc. | Aqueous solution formulations of vancomycin |
| GB201609940D0 (en) | 2016-06-07 | 2016-07-20 | Novabiotics Ltd | Microparticles |
| CN110087653A (en) | 2016-10-27 | 2019-08-02 | 普尔莫凯恩股份有限公司 | For treating the combination treatment of pulmonary hypertension |
| CN106963939A (en) * | 2017-03-22 | 2017-07-21 | 永信药品工业（昆山）股份有限公司 | Vancomycin hydrochloride pharmaceutical composition and preparation method thereof |
| CA3062567A1 (en) | 2017-05-22 | 2018-11-29 | Insmed Incorporated | Glycopeptide derivative compounds and uses thereof |
| JP7460534B2 (en) | 2018-03-30 | 2024-04-02 | インスメッド インコーポレイテッド | Continuous manufacturing method for liposome medicines |
| EP3866829A1 (en) * | 2018-10-15 | 2021-08-25 | Savara Inc. | Separation of vancomycin and its degradation products |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| IE56059B1 (en) | 1982-10-08 | 1991-04-10 | Glaxo Group Ltd | Devices for administering medicaments to patients |
| GR861995B (en) | 1985-07-30 | 1986-11-04 | Glaxo Group Ltd | Devices for administering medicaments to patients |
| JPH03193735A (en) * | 1989-12-22 | 1991-08-23 | Shionogi & Co Ltd | Stabilized composition of glycopeptide-based antibiotic |
| JPH05963A (en) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | Polypeptide composition |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US6051256A (en) * | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| JP4142149B2 (en) * | 1997-07-10 | 2008-08-27 | 明治製菓株式会社 | Vancomycin lyophilized formulation |
| US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| KR100702878B1 (en) * | 1999-10-29 | 2007-04-04 | 넥타르 테라퓨틱스 | Dry powder compositions having improved dispersivity |
| EP1446104B2 (en) * | 2001-11-01 | 2011-08-03 | Novartis AG | Spray drying methods |
| DE10358387A1 (en) * | 2003-12-13 | 2005-07-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder containing low molecular weight dextran and process for their preparation |
| FR2872044B1 (en) * | 2004-06-28 | 2007-06-29 | Flamel Technologies Sa | PHARMACEUTICAL FORMULATION BASED ON ANTIBIOTICS IN THE MICROCAPSULAR FORM |
| EP2050437A1 (en) * | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
| NZ592717A (en) * | 2008-10-07 | 2013-03-28 | Mpex Pharmaceuticals Inc | Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation |
| ES2625260T5 (en) | 2009-03-26 | 2020-07-29 | Pulmatrix Operating Co Inc | Dry powder formulations and methods for the treatment of lung diseases |
| US20120058198A1 (en) | 2009-03-26 | 2012-03-08 | Pulmatrix, Inc. | Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis |
-
2012
- 2012-05-21 WO PCT/US2012/038775 patent/WO2012159103A1/en active Application Filing
- 2012-05-21 SG SG2013085394A patent/SG195038A1/en unknown
- 2012-05-21 EP EP12785744.9A patent/EP2709646A4/en not_active Withdrawn
- 2012-05-21 MX MX2013013503A patent/MX346244B/en active IP Right Grant
- 2012-05-21 CA CA2836643A patent/CA2836643C/en not_active Expired - Fee Related
- 2012-05-21 CN CN201280035537.0A patent/CN103717231B/en not_active Expired - Fee Related
- 2012-05-21 BR BR112013029803-0A patent/BR112013029803B1/en not_active IP Right Cessation
- 2012-05-21 JP JP2014511611A patent/JP6012716B2/en not_active Expired - Fee Related
- 2012-05-21 KR KR1020137033895A patent/KR101763195B1/en active IP Right Grant
- 2012-05-21 AU AU2012254999A patent/AU2012254999B2/en not_active Ceased
- 2012-05-21 CA CA2981038A patent/CA2981038C/en not_active Expired - Fee Related
-
2013
- 2013-11-19 IL IL229506A patent/IL229506B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014515356A (en) | 2014-06-30 |
| CA2836643C (en) | 2017-11-14 |
| NZ618002A (en) | 2015-03-27 |
| SG195038A1 (en) | 2013-12-30 |
| MX2013013503A (en) | 2014-05-12 |
| WO2012159103A1 (en) | 2012-11-22 |
| CN103717231B (en) | 2016-08-17 |
| IL229506B (en) | 2019-07-31 |
| KR101763195B1 (en) | 2017-07-31 |
| EP2709646A4 (en) | 2015-05-13 |
| EP2709646A1 (en) | 2014-03-26 |
| BR112013029803B1 (en) | 2021-07-13 |
| CN103717231A (en) | 2014-04-09 |
| MX346244B (en) | 2017-03-13 |
| KR20140032450A (en) | 2014-03-14 |
| CA2836643A1 (en) | 2012-11-22 |
| CA2981038A1 (en) | 2012-11-22 |
| JP6012716B2 (en) | 2016-10-25 |
| BR112013029803A2 (en) | 2017-01-17 |
| NZ704819A (en) | 2016-05-27 |
| CA2981038C (en) | 2018-09-25 |
| AU2012254999B2 (en) | 2016-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL229506A0 (en) | Dry powder vancomycin compositions and associated methods | |
| HK1199694A1 (en) | Probiotic compositions and methods | |
| ZA201408594B (en) | Xylitol-based anti-mucosal compositions and related methods and compositions | |
| EP2591359A4 (en) | Methods and compositions for quantifying exosomes | |
| EP2624702A4 (en) | Anti-biofilm compositions and methods for using | |
| ZA201306316B (en) | Methods and compositions for preparing noribogaine from voacangine | |
| EP2691397A4 (en) | Methods and compositions for preparing noribogaine from voacangine | |
| EP2629742A4 (en) | Hair-mending compositions and associated methods | |
| GB201102237D0 (en) | Particle formulation | |
| ZA201304201B (en) | Composition comprising insecticide-wax particles | |
| EP2854530A4 (en) | Compositions and methods for -glucan immunotherapy | |
| EP2785176A4 (en) | Anti-microbial compositions and related methods | |
| EP2555788A4 (en) | Methods and compositions for cardioprotection and cardioregeneration | |
| IL250307A0 (en) | Fumigant compositions and methods | |
| GB201315350D0 (en) | Methods and compositions | |
| ZA201304122B (en) | Methods and compositions for drying coal | |
| EP2762129A4 (en) | Cosmetic composition and cosmetic | |
| GB201315347D0 (en) | Methods and compositions | |
| HK1201451A1 (en) | Compositions and methods | |
| EP2575869A4 (en) | Peptide particle formulation | |
| EP2668044A4 (en) | Compositions and their use | |
| GB201018650D0 (en) | Methods and compositions | |
| ZA201308892B (en) | Compositions and methods | |
| EP2766357A4 (en) | Meso-biliverdin compositions and methods | |
| GB201106357D0 (en) | Composition and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |